Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer

Journal of Immunological Methods

Volumn 387, Issue 1-2, 2013, Pages 114-120

  Sun, Lan ^a   Tu, Lingli ^a   Gao, Guangping ^d   Sun, Xun ^b   Duan, Jiachuan ^c   Lu, You ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c National Chengdu Center for Safety Evaluation of Drugs   (China)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Adeno associated virus; Neutralizing antibodies; Passive immunity

Indexed keywords

NEUTRALIZING ANTIBODY;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; IMMUNOASSAY; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHESUS MONKEY; SENSITIVITY ANALYSIS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, NEUTRALIZING; CAPSID PROTEINS; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNITY; IMMUNIZATION, PASSIVE; MACACA MULATTA; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL;

ADENO-ASSOCIATED VIRUS; MACACA MULATTA; MIRIDAE; MUS; PRIMATES;

EID: 84871414715     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.10.003     Document Type: Article

References (28)

1. Bainbridge J.W., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., Viswanathan A., Holder G.E., Stockman A., Tyler N., Petersen-Jones S., Bhattacharya S.S., Thrasher A.J., Fitzke F.W., Carter B.J., Rubin G.S., Moore A.T., Ali R.R. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 2008, 358:2231.
2. Boutin S., Monteilhet V., Veron P., Leborgne C., Benveniste O., Montus M.F., Masurier C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 2010, 21:704.
3. Breous E., Somanathan S., Wilson J.M. BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver. Mol. Ther. 2010, 18:766.
4. Chao H., Walsh C.E. Induction of tolerance to human factor VIII in mice. Blood 2001, 97:3311.
5. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999, 6:1574.
6. Crowe J.E., Suara R.O., Brock S., Kallewaard N., House F., Weitkamp J.H. Genetic and structural determinants of virus neutralizing antibodies. Immunol. Res. 2001, 23:135.
7. Davidoff A.M., Ng C.Y., Sleep S., Gray J., Azam S., Zhao Y., McIntosh J.H., Karimipoor M., Nathwani A.C. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J. Virol. Methods 2004, 121:209.
8. Eberling J.L., Jagust W.J., Christine C.W., Starr P., Larson P., Bankiewicz K.S., Aminoff M.J. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008, 70:1980.
9. Evans V.C., Graham I.R., Athanasopoulos T., Galley D.J., Jackson C.L., Simons J.P., Dickson G., Owen J.S. Adeno-associated virus serotypes 7 and 8 outperform serotype 9 in expressing atheroprotective human apoE3 from mouse skeletal muscle. Metabolism 2010, 60:491.
10. Franco L.M., Sun B., Yang X., Bird A., Zhang H., Schneider A., Brown T., Young S.P., Clay T.M., Amalfitano A., Chen Y.T., Koeberl D.D. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol. Ther. 2005, 12:876.
11. Gao G., Vandenberghe L.H., Wilson J.M. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 2005, 5:285.
12. Gao G.P., Lu Y., Sun X., Johnston J., Calcedo R., Grant R., Wilson J.M. High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. J. Virol. 2006, 80:6192.
13. Gao G., Wang Q., Calcedo R., Mays L., Bell P., Wang L., Vandenberghe L.H., Grant R., Sanmiguel J., Furth E.E., Wilson J.M. Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum. Gene Ther. 2009, 20:930.
14. Gao G., Bish L.T., Sleeper M.M., Mu X., Sun L., Lou Y., Duan J., Hu C., Wang L., Sweeney H.L. Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques. Hum. Gene Ther. 2011, 22:979.
15. Hurlbut G.D., Ziegler R.J., Nietupski J.B., Foley J.W., Woodworth L.A., Meyers E., Bercury S.D., Pande N.N., Souza D.W., Bree M.P., Lukason M.J., Marshall J., Cheng S.H., Scheule R.K. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol. Ther. 2010, 18:1983.
16. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., Bland R.J., Young D., Strybing K., Eidelberg D., During M.J. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369:2097.
17. Klasse P.J., Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 2002, 83:2091.
18. Li H., Malani N., Hamilton S.R., Schlachterman A., Bussadori G., Edmonson S.E., Shah R., Arruda V.R., Mingozzi F., Wright J.F., Bushman F.D., High K.A. Assessing the potential for AAV vector genotoxicity in a murine model. Blood 2010, 117:3311.
19. Manno C.S., Pierce G.F., Arruda V.R., Glader B., Ragni M., Rasko J.J., Ozelo M.C., Hoots K., Blatt P., Konkle B., Dake M., Kaye R., Razavi M., Zajko A., Zehnder J., Rustagi P.K., Nakai H., Chew A., Leonard D., Wright J.F., Lessard R.R., Sommer J.M., Tigges M., Sabatino D., Luk A., Jiang H., Mingozzi F., Couto L., Ertl H.C., High K.A., Kay M.A. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 2006, 12:342.
20. Moskalenko M., Chen L., van Roey M., Donahue B.A., Snyder R.O., McArthur J.G., Patel S.D. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 2000, 74:1761.
21. Murphy S.L., Li H., Mingozzi F., Sabatino D.E., Hui D.J., Edmonson S.A., High K.A. Diverse IgG subclass responses to adeno-associated virus infection and vector administration. J. Med. Virol. 2009, 81:65.
22. Nathwani A.C., Rosales C., McIntosh J., Rastegarlari G., Nathwani D., Raj D., Nawathe S., Waddington S.N., Bronson R., Jackson S., Donahue R.E., High K.A., Mingozzi F., Ng C.Y., Zhou J., Spence Y., McCarville M.B., Valentine M., Allay J., Coleman J., Sleep S., Gray J.T., Nienhuis A.W., Davidoff A.M. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol. Ther. 2011, 19:876.
23. Scallan C.D., Jiang H., Liu T., Patarroyo-White S., Sommer J.M., Zhou S., Couto L.B., Pierce G.F. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 2006, 107:1810.
24. Snyder R.O., Miao C.H., Patijn G.A., Spratt S.K., Danos O., Nagy D., Gown A.M., Winther B., Meuse L., Cohen L.K., Thompson A.R., Kay M.A. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 1997, 16:270.
25. Tamai H., Miyake K., Yamaguchi H., Takatori M., Dan K., Inokuchi K., Shimada T. AAV-8 vector expressing IL-24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice. Blood 2011.
26. Wang L., Calcedo R., Nichols T.C., Bellinger D.A., Dillow A., Verma I.M., Wilson J.M. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 2005, 105:3079.
27. Wang L., Calcedo R., Wang H., Bell P., Grant R., Vandenberghe L.H., Sanmiguel J., Morizono H., Batshaw M.L., Wilson J.M. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol. Ther. 2010, 18:126.
28. Zaiss A.K., Muruve D.A. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther. 2008, 15:808.